Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential PEG-IFNα-2b Plus TKI vs TKI Alone for Treatment-Free Remission in Chronic Phase CML
ChiCTR2600130452Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in chronic myelogenous leukemia (CML) (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Proportion of patients with loss of major molecular response (MMR) at Week 96 and Proportion of treatment-free remission (TFR) at Week 96. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2600130452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130452.